MEDI5752 + paclitaxel

MEDI5752 + paclitaxel is a combination therapy under clinical investigation for advanced solid tumors, most notably metastatic non-small cell lung cancer. **MEDI5752** (also called volrustomig) is a novel monovalent bispecific antibody that simultaneously targets the **programmed cell death protein 1 (PD-1)** and **cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)** immune checkpoints, delivering preferential CTLA-4 blockade on PD-1 positive activated T cells in the tumor microenvironment. This design aims to boost antitumor immune response while reducing the toxicity associated with dual checkpoint inhibition. **Paclitaxel** is a well-established chemotherapeutic agent that stabilizes microtubules, inhibiting cell division and leading to apoptosis. The combination is under evaluation as first-line treatment for metastatic non-small cell lung cancer and other advanced malignancies[1][2][3].

Brand names

volrustomig

Other names

MEDI5752 + paclitaxelvolrustomig + paclitaxel